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Sachin M. Patil and Parag Patel
Abstract
Of all the medications available to physicians worldwide, antibiotics play an
essential role in inpatient and outpatient settings. Discovered in the early nine-
teenth century by Alexander Fleming, penicillin was the first antibiotic isolated
from a mold. Dr. Gerhard Domagk developed synthetic sulfa drugs by altering the
red dye used in chemical industries. Since then, multiple antibiotic classes have
been discovered with varying antimicrobial effects enabling their use empirically or
in specific clinical scenarios. Antibiotics with different mechanisms of action could
be either bactericidal or bacteriostatic. However, no clinical significance has been
observed between cidal and static antibiotics in multiple trials. Their presence has
led to safer deep invasive surgeries, advanced chemotherapy in cancer, and organ
transplantation. Indiscriminate usage of antibiotics has resulted in severe hospital-
acquired infections, including nosocomial pneumonia, Clostridioides difficile infec-
tion, multidrug-resistant invasive bacterial infections, allergic reactions, and other
significant side effects. Antibiotic stewardship is an essential process in the modern
era to advocate judicial use of antibiotics for an appropriate duration. They play a
vital role in medical and surgical intensive care units to address the various compli-
cations seen in these patients. Antibiotics are crucial in severe acute infections to
improve overall mortality and morbidity.
Keywords: Sepsis, antibiotics, bactericidal, bacteriostatic, stewardship
1. Introduction
Antibiotic is a term used to define a chemical substance produced by one micro-
organism that stunts the metabolism and development of other organisms [1]. The
antibiotic term was used initially for naturally acquired substances; however, now
the term encompasses both natural and synthetic antimicrobial substances.
Although penicillin was the first antibiotic isolated from the mold, it was super-
seded by sulfa drugs used by physicians to treat infections successfully [2]. Due to
antibiotic use, the infectious disease death rate has declined from 280 per 100,000
to 60 per 100,000 in the 1950s [3]. A common belief is that cidal antibiotics are
efficient than static antibiotics with no clinical evidence supporting it. Both cidal
and static are invitro terms which, refer to the effect of antibiotic concentrations
affecting bacterial growth at a predefined threshold. They cannot predict the infec-
tion outcome in vivo. Antibiotics targeting the organism’s cell wall are mostly
bactericidal, whereas those targeting protein syntheses are bacteriostatic. MIC
(minimum inhibitory concentration) is the lowest antibiotic concentration, which
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prevents visible growth at 24 hours. MBC (minimum bactericidal concentration) is
the minimal concentration of antibiotics that causes bacterial death. Breakpoints for
antibiotic MIC’s are set by the the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) and National Committee for Clinical and Laboratory
Standards Institute (CLSI). A bactericidal antibiotic MBC is less than or equal to
four folds above the MIC, accounting for a 1000-fold decline in bacterial density
[4]. A bacteriostatic antibiotic achieves a > 1000-fold reduction at eight-fold above
MIC or a 500-fold reduction in bacterial density at 4-fold above its MIC. They are
still labeled as static despite the clear demonstration of bacterial killing. An antibi-
otic becomes more bactericidal as the MIC moves closer to the MBC. Bacteriostatic
agents have an MBC to MIC ratio > than that for bactericidal antibiotics.
A systematic literature review revealed no confirmation that cidal agents are
better than static agents [5]. In addition, there was no substantial difference in
efficiency, including critically ill patients with severe infections and sepsis. Six trials
demonstrated the superiority of static agent linezolid over cidal agents such as
vancomycin [5]. A single trial showed the efficiency of cidal agent imipenem over
tigecycline; however, the dose of tigecycline was small, and with increased appro-
priate dosing, the efficacy disappeared [6, 7]. A rapidly bactericidal agent such as
daptomycin does not perform better than a slowly cidal agent such as vancomycin
to treat right-sided infective endocarditis (IE) and staphylococcal bacteremia [8] . A
synergistic combination of beta-lactam with aminoglycosides enhances the bacteri-
cidal effect with rapid blood clearance [9]. However, this synergistic combination
has not improved clinical outcomes or mortality [10]. In the initial studies, static
agents such as tetracyclines and macrolides were inferior to cidal agents in IE
therapy [11]. This assumption can be erroneous as the static agents do not achieve
adequate low blood concentrations to treat infective endocarditis effectively. A
bacteriostatic antibiotic such as linezolid can attain sufficient bloodstream concen-
trations resulting in higher cure rates for IE [12]. Daptomycin, a rapidly bactericidal
agent, is inferior to vancomycin in left-sided IE [13]. For an individual antibiotic to
be effective, the importance of its pharmacokinetic-pharmacodynamic properties
and attaining adequate drug levels at the infection site is substantial than static
versus cidal properties used in predicting clinical efficacy. An intact immune system
is critical for the efficacy of bacteriostatic agents, and bactericidal agents are pre-
ferred in immunosuppressed patients. Broad-spectrum agents cover many suscep-
tible pathogens, whereas narrow-spectrum agents cover a limited number of
pathogens. Broad-spectrum agents are used empirically in the therapy of lung and
abdominal infections. Narrow-spectrum agents are used in a limited number of
indications.
2. Bacteriostatic antibiotics
These include folate inhibitors (sulfonamides and trimethoprim) in Table 1
(2A I), tetracyclines in Table 2 (2A II), glycylcyclines in Table 3 (2A III),
macrolides in Table 4 (2A IV), lincosamides in Table 5 (2A V), oxazolidinones in
Table 6 (2A VI) and fusidic acid in Table 7 (2A VII).
Dapsone can substitute sulfamethoxazole in the TMP-SMX combination for PCJ
pneumonia in patients with allergies to sulfonamide antibiotics [89]. TMP-SMX is
the drug of choice for Q-fever in pregnancy. An essential fact to remember is that
TMP-SMX does not cover pseudomonas and should be avoided in streptococcal
infections due to a higher incidence of resistance [90]. Iclaprim is a DHFR inhibitor
with bactericidal activity against methicillin-sensitive Staphylococcus aureus (MSSA),
Methicillin-resistant (MRSA), beta-hemolytic Streptococcal spp, and Enterococcus
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faecalis. It undergoes hepatic clearance, and dose adjustment is needed in hepatic
impairment. Tissue penetration is excellent in the lungs. It is effective without a
sulfa moiety so that it can be used in patients with sulfa allergy. The side effects
include nausea, headache, fatigue, and QT interval prolongation. Currently, it is
under trials for SSTI and nosocomial pneumonia [91, 92].
Doxycycline is the drug of choice in bioterrorism caused by Bacillus anthracis,
Yersinia pestis, Francisella tularensis, Coxiella burnetti, and Brucella spp [93]. In the
medical intensive care unit (MICU), tetracyclines are the drug of choice in acute
sepsis due to cholera, ehrlichiosis, stenotrophomonas infections, rickettsial disease,
anaplasmosis, and PID.
In sepsis, tigecycline is used in MDR infections as a last resort, and the federal
drug authority (FDA) has placed a boxed warning about this death risk. It can also
be used effectively at a higher dosage in MDR hospital-acquired pneumonia (HAP)
and ventilator-associated pneumonia (VAP).
Origin Sulfonamides are sulfanilamide derivatives identical to para-aminobenzoic acid
(PABA) required for folic acid synthesis in most bacteria.
Trimethoprim is a synthetic derivative from trimethoxybenzyl-pyrimidine [14].
Mechanism of
action
Sulfonamides antagonize PABA inclusion into dihydropteroate by its greater affinity
for tetrahydropteroic acid synthetase in microorganisms resulting in decreased
dihydrofolic acid, a substrate for dihydrofolate reductase (DHFR) [15, 16].
Trimethoprim is a potent bacterial inhibitor of DFR, preventing the formation of
tetrahyrofolic acid needed for purine and deoxyribonucleic acid [14].
Thus, sulfonamides and trimethoprim together stop two consecutive steps essential in
the folic acid synthesis. A combination of both is synergistic and bactericidal in
trimethoprim and the sulfa ratio of 1:20 [17].
Routes Sulfonamides are available in oral, intravenous (IV), topical, and ophthalmic
formulations.
Trimethoprim is available in oral and intravenous formulations.
Indication Sulfonamides: Nocardiosis, Toxoplasmosis, Plasmodium falciparum malaria,
Nongonococcal urethritis,
Trimethoprim: Acute urinary tract infection (UTI), Recurrent UTI
Trimethoprim and sulfamethoxazole (TMP-SMX): Above indications plus UTI, Skin
and soft tissue infections (SSTI) due to Staphylococcus aureus, Pneumocystis jiroveci
(PCJ) pneumonia, and prophylaxis, Melioidosis, Whipple disease, Alternative in
Listeria meningitis
Resistance Sulfonamides: Point mutations in folP gene modifying dihydropteroate synthetase
resulting in decreased affinity for sulfonamide [18]. PABA binding site alteration due
to F28L/T and P64S mutations [19]. Integrons sul1, sul2, and sul3 coding drug
resistance enzymes [20].
Trimethoprim: Plasmid-mediated resistant DHFR enzyme
Pharmaco-
kinetics
Sulfonamides: Well distributed throughout the body, and protein binding predicts the
blood and tissue levels. It is metabolized in the liver (CYP2C9 & CYP3A4 hepatic
enzyme system) and excreted via renal excretion. Chronic kidney disease results in
decreased renal clearance [21]. It can interact with multiple other drugs resulting in
increased serum levels and toxicity especially antiseizure medications.
Toxicity Skin: Rashes, Steven-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)
[22, 23].
Blood: Anemia, agranulocytosis, thrombocytopenia, methemoglobinemia [24].
Renal: Hyperkalemia, Acute renal failure, Interstitial nephritis,
Lactic acidosis [24–26].




2AI folate inhibitors: Sulfonamides & trimethoprim.
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Origin Tetracycline is derived from catalytic dehalogenation of chlortetracycline obtained
from Streptomyces rimosus [30].
Doxycycline and Minocycline are semisynthetic derivatives of oxytetracycline.
Mechanism of
action
Reversibly binds 30S ribosomal subunit of the bacteria and inhibits protein
synthesis. In protozoa, it additionally binds to 70S ribosome and stops protein
synthesis [30, 31].
Routes Orally via capsules, tablets, syrups, and IV formulations.
Indication Community-acquired bacterial pneumonia (CABP), MSSA &MRSA SSTI,
Stenotrophomonas infections, Helicobacter pylori infection, Nongonococcal
urethritis, Lyme disease, Rickettsial infections, Nocardiosis, Falciparum malaria,
Cholera, Anaplasmosis, and Ehrlichiosis. Q fever, Brucellosis, Melioidosis, Acne
vulgarism, the second line in syphilis, and a part of the combination regimen in
pelvic inflammatory disease (PID).
Resistance It is mediated mainly by active efflux pumps and ribosomal protection proteins.
Other minor mechanisms include antibiotic enzymatic lysis, a decline in-wall
permeability, and binding site alterations [32].
Pharmac-
okinetics
Unlike tetracycline, food does not substantially alter doxycycline and minocycline
absorption, and both have excellent bioavailability [33]. Lipid solubility determines
the tissue and fluid levels of which minocycline > doxycycline > tetracycline. At
higher doses, doxycycline reaches adequate levels in the cerebrospinal fluid (CSF)




GI: pill-induced esophagitis, heartburn, epigastric pain, nausea, vomiting, acid
reflux disorder [35]. Hepatotoxicity from IV tetracycline [36]. Skin: photosensitive
rash and hyperpigmentation of body parts [37]. Nephrogenic diabetes insipidus: by
demeclocycline [38]. Central Nervous System(CNS): Vestibular symptoms,
Pseudotumor cerebri Teeth, and Bone: tooth staining, enamel hypoplasia, and
diminished bone growth in premature infants exposed to tetracycline [39].
Hypersensitivity reactions: facial swelling, drug-induced lupus, anaphylaxis,
urticaria [40]. Tetracyclines are teratogenic and reach the fetus via the placenta.
Table 2.
2A II tetracyclines.




Its reversal binding to 30S ribosomes is stronger by five times, and ribosomal
protection proteins do not affect it [42, 43].
Routes Due to poor oral absorption, it is available in IV formulations.
Indication Complicated SSTI, Complicated intraabdominal infections (cIAIs), CABP, Used as
salvage therapy in critically ill patients when no other alternatives exist for
multidrug-resistant infections (MDR).
Resistance It is due to increased efflux pumps such as AcrAB and MexAB-OprM after detecting




Adequate tissue distribution was observed with a half-life of 37 to 67 hours and a
plasma protein binding of about 80% [46]. No dose adjustment is required in renal
impairment and mild to moderate hepatic impairment. Dose adjustment is needed
for severe hepatic impairment. It is not removed by hemodialysis [47]. It is excreted
by the liver and minimally by the kidney.
Toxicity/Adverse
effects
GI: nausea, vomiting, transaminase elevation, acute pancreatitis. Others: infection,
phlebitis, headache, dizziness, skin rash [47]. It is associated with increased
mortality compared to other antibiotics used for the same indication. 13 clinical
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Origin Erythromycin was obtained from Streptomyces erythreus present in the soil. Azithromycin
and Clarithromycin are semisynthetic derivatives from erythromycin, which improve
stability in gastric acid [49].
Mechanism of
action
Macrolides bind to 23S ribosomal ribonucleic acid (rRNA), a subunit of the 50S subunit of
the bacterial ribosome, and stop the RNA-based synthesis of proteins [50]. Bactericidal
activity is seen against , Hemophilus influenzae, and Streptococcus pneumoniae.
Routes It is available as oral liquid, tablet, capsule, IV, ophthalmic and topical preparations.
Indication Erythromycin: used as an alternative to penicillin (PCN) in allergic patients. Treatment and
preexposure prophylaxis in pertussis. Azithromycin: CABP, Pertussis, Trachoma,
Chancroid, Babesiosis, Mycobacterium avium complex (MAC) infections, alternative for
Lyme disease, sinusitis, pharyngitis, and acute otitis media. Clarithromycin: Helicobacter
pylori infection, Nontubercular mycobacterial infection, Campylobacter enteritis, MAC
infections
Resistance 50S ribosomal protein mutations or 23S rRNA receptor alterations confer resistance to
macrolides (M), lincosamides (L), and streptogramin B (SB) (MLSB phenotype). Erm
(erythromycin ribosome methylation) genes present on transposons or plasmids mediate
this effect [51, 52].
Pharmac-
okinetics
Erythromycin is metabolized by hepatic CYP3A cytochrome subclass of cytochrome 450
system. It is incompatible with other IV preparations [53, 54]. It follows total body water
distribution [55] and persists in tissues longer than in blood. Oral azithromycin
bioavailability is around 37% [56]. It is well distributed in tissues with levels > than in blood
by 10 to 100 fold. It is excreted primarily unchanged via hepatic clearance into the feces.
No dose adjustments are required for renal and hepatic impairment. Clarithromycin oral
bioavailability is 55%, has excellent tissue distribution, and undergoes mainly hepatic




Erythromycin: GI side effects (nausea, vomiting, and abdominal pain), Thrombophlebitis,
Allergic reactions, Ototoxicity, Torsades de pointes. Clarithromycin and Azithromycin: GI




Origin Lincomycin is derived from Streptomyces lincolnensis present in the soil. Clindamycin
is semisynthetically by chemically modifying lincomycin resulting in increased
potency and bioavailability [61].
Mechanism of
action
It binds to 50S ribosomal sites and inhibits protein synthesis, and competes with
macrolides for the same site.
Routes Available in IV, oral capsules and liquid solution, topical gel, foam or solution, and
vaginal cream or suppository.
Indication Gram-positive or anaerobic SSTI, acne vulgaris, part of the combination regimen
against toxoplasmosis, falciparum malaria, and Pneumocystis jiroveci pneumonia.
Resistance MLSB phenotype regulated by the ermA or ermC genes [62]. rRNA mutations,




90% oral bioavailability with good tissue levels except in CSF [61, 66]. It is
metabolized by the liver, and excretion occurs via feces and urine [67]. Dosing
adjustment is needed in severe renal and hepatic impairment
Toxicity/Adverse
effects
Cutaneous drug reactions in patients with (human leukocyte antigen)HLA-B*51:01
genotype including maculopapular eruptions, erythema multiforme, urticaria, drug
rash with eosinophilia, and systemic symptoms (DRESS), SJS, TEN [68]. GI:
diarrhea, pseudomembranous colitis by Clostridioides difficile, reversible
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Two other newer tetracycline derivatives have been released Eravacycline, a
fluorocycline, and Omadacycline, an aminomethylcycline., while omadacycline has
been approved for SSTI and CABP. In contrast, Eravacycline has been approved for
cIAI [94, 95]. Similar to tigecycline, neither of these agents cover pseudomonas.
Origin Linezolid and Tedizolid are derived from 5-(halomethyl)-3-aryl-2-oxazolidinones




Halts bacterial protein synthesis by binding to the V-domain of 23S RNA, a part of
the 50S ribosomal unit [70]. Efficacy is proportional to the drug level area under the
curve AUC/MIC ratio.
Routes Available as oral tablets and IV formulations.
Indication Linezolid: MSSA/MRSA nosocomial pneumonia, CABP, Gram-positive complicated
and uncomplicated SSTI, Vancomycin-resistant Enterococcus (VRE) infections,
Nocardiosis. Tedizolid: Gram-positive SSTI.
Resistance It is <1% and due to 23S rRNA domain V region receptor site mutation, cfr
(chloramphenicol-florfenicol resistance) ribosomal RNA methyltransferase, and
optrA causing adenylation [71–73].
Pharmac-
okinetics
Linezolid: oral bioavailability is 100%, excellent tissue distribution, and 31% plasma
protein-bound [74]. It is oxidized and renally excreted. No dosage adjustment is
needed. Tedizolid: oral bioavailability is 91% with adequate tissue distribution and
80% plasma protein-bound. It undergoes hepatic clearance with 20% excreted
renally. No dosage adjustment is needed [75, 76].
Toxicity/Adverse
effects
Blood: Thrombocytopenia, pancytopenia, pure red cell aplasia, and reversible
myelosuppression [77]. Mitochondrial toxicity: lactic acidosis, peripheral and optic
neuropathy [78–80]. Others: Serotonin syndrome with serotonergic medications,
tooth and tongue discoloration, and hypoglycemia [78, 81, 82].
Table 6.
2A VI oxazolidinones.
Origin It was derived from the fungus Fusidium coccineum.
Mechanism of
action
It inhibits protein synthesis by preventing the translocation, elongation phase, and
blocking the elongation factor G (EF-G) effect on the ribosome, making the bacteria
susceptible to phagocytosis due to reduced surface proteins [83, 84]. It is active
against MSSA, MRSA, Coagulase-negative staphylococci, Clostridium spp,
Peptostreptococcus, and most anaerobes except for Fusoabcterium spp.
Routes Available in oral, eye, topical, and IV formulations.
Indication As a part of a combination regimen against staphylococcal SSTI and bone infections,
especially with rifampin or beta-lactams.
Resistance Chromosomal or plasmid-mediated mutations in the gene encoding the EF-G (fusA,
fusB, fusC, and fusE).
Pharmac-
okinetics
Newer film-coated tablets have better oral bioavailability, highly plasma protein-
bound with adequate intracellular and tissue penetration [85, 86]. It undergoes
hepatic metabolism and needs dose adjustment with hepatic impairment [87].
Toxicity/Adverse
effects
Nausea, diarrhea, vomiting, and elevated bilirubin due to bile transport blockade.
When used along with statin, the risk of rhabdomyolysis is observed after 20 to
30 days after therapy initiation [88].
Table 7.
2A VII fusidane (fusidic acid).
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No dosing modification is needed for renal or hepatic impairment. They are
teratogenic, and the anticoagulant dose needs adjustment when used concomi-
tantly. A slightly increased mortality was observed in the CABP trial of
omadacycline [94].
Azithromycin is an excellent choice for treating CABP caused by atypical organ-
isms such as Mycoplasma pneumoniae, Legionella spp., Chlamydia pneumoniae, and
Coxiella burnetti. An important fact is to remember the numerous interactions this
class has with other medications, and also, it can prolong the QT interval resulting
in ventricular tachyarrythmias.
When used in the therapy for staphylococcal infections, it is prudent always to
perform a “D” test to identify any chance of inducible resistance. It is recommended
not to use clindamycin as an empirical regimen against streptococcal infections due
to a higher risk of resistance. Clindamycin can suppress the cyclosporine effect and
can cause neuromuscular blockade.
Linezolid is an alternative for vancomycin in MRSA/MSSA pneumonia and is
used in combination regimens for nosocomial pneumonia. It is an alternative in
Nocardiosis and a part of combination regimens in the therapy of Mycobacterium
tuberculosis, Mycobacterium avium complex, and Mycobacterium abscessus complex.
3. Bactericidal antibiotics
These include glycopeptides in Table 8 (3A I), lipoglycopeptides in Table 9 (3A
II), lipopeptides in Table 10 (3A III), aminoglycosides in Table 11 (3A IV),
quinolones in Table 12 (3A V), penicillin in Table 13 (3A VI), cephalosporins in
Table 14 (3A VII), beta-lactamase and beta-lactamase inhibitor combinations in
Table 15 (3A VIII), monobactams in Table 16 (3A IX), carbapenems in Table 17
(3A X), polymixins in Table 18 (3A XI), epoxide in Table 19 (3A XII),
pleuromutilin in Table 20 (3A XIII), rifamycins in Table 21 (3A XIV) and
metronidazole in Table 22 (3A XV).
An increased risk of renal failure is observed when vancomycin is administered
along with aminoglycosides and piperacillin-tazobactam [218, 219]. If a VRE strain
susceptibility reveals sensitivity to teicoplanin, it should be avoided due to resis-
tance emergence during therapy. When teicoplanin is used for IE, bone, and joint
infections as a monotherapy, the recommendation is to keep serum levels close to
20 μg/mL and, if needed >30 μg/mL [220]. A higher AUC/MIC ratio is related to
better clinical outcomes and decreased mortality with vancomycin therapy [221].
The lipoglycopeptides have a longer half-life and are currently undergoing trials
for bacteremia, joint infections, osteomyelitis.
Retrospective data indicate higher cure rates and lower mortality when a higher
dose (> 8 mg/kg/day) of daptomycin is used [222]. In the therapeutic failure of
vancomycin therapy, a suggestion is to use a higher dose of daptomycin or combine
it with a beta-lactam or aminoglycoside or TMP-SMX to increase its bactericidal
activity. In VRE endocarditis with bacteremia, daptomycin with beta-lactam is an
ideal combination to prevent the emergence of resistance [223, 224]. Due to lack of
CNS penetration, it should not be used in the therapy for meningitis [225].
Daptomycin is inactivated by the pulmonary surfactant and is rendered ineffective
in bronchoalveolar pneumonia but is adequate in hematogenous pneumonia [226].
In patients with chronic kidney disease and on dialysis, more frequent monitoring
of CPK is ideal. CPK monitoring is a must if the patient is on statins for hyperlipid-
emia. It needs to be stopped if the CPK levels are >1000 units/L with clinical
features of myopathy or > 2000 (ten times the upper limit) with no myopathy
features [123].
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Streptogramins are another class of lipopeptides rarely used currently. They are
made up of two macrocyclic lactone peptolide components. They are labeled as
streptogramin A, and streptogramin B. Quinupristin-Dalfopristin is a 30: 70 ratio IV
formulation available for therapy. These components are bacteriostatic as dalfopristin
ends protein synthesis by binding to 50S ribosomal unit and quinupristin prevents
peptide elongation. Dalfopristin binding increases the affinity to quinupristin due to
structural change resulting in synergistic bactericidal activity. It is currently used as
an alternative for MSSA or streptococcal SSTI. It needs a central line for administra-
tion as it is an irritant and can cause thrombophlebitis [227].
Origin Vancomycin was derived from Amycolatopsis orientalis. Teicoplannin was isolated
from Actinoplanes teichomyceticus. Teicoplanin has not been approved in the United
States as it did not offer any advantage over vancomycin.
Mechanism of
action
Cell wall synthesis is stopped by inhibition of transpeptidation and disaccharide
subunits incorporation into peptidoglycan.
Routes Vancomycin is available in oral, IV, intrathecal, intraventricular, intraperitoneal,
and intraocular formulations. Teicoplanin is available in oral, intramuscular, and IV
formulations.
Indication Vancomycin: Gram-positive and MRSA SSTI, MRSA bacteremia, MRSA native and
prosthetic valve IE, Vancomycin sensitive Enterococcal IE, Corynebacterium jeikeium
and striatum infections, MRSA meningitis, and ventriculitis, MRSA pneumonia,
joint infections, and osteomyelitis. Pseudomembranous colitis by Clostridioides
difficile, Febrile neutropenia, Pre-procedure surgical prophylaxis.
Teicoplanin: MRSA bacteremia, Gram-positive and MRSA SSTI, Alternative for IE
due to Streptococci viridans and Enterococci, Pseudomembranous colitis by
Clostridioides difficile, Pre-procedure surgical prophylaxis.
Resistance Vancomycin: mecA and mecC encode for a low-affinity penicillin-binding protein
PBP2a and PBP2c. Some MRSA strains acquire the VanA gene from enterococci
species. Enterococci with VanA, VanB, VanC, VanD, VanE, VanG, VanL, VanM and
VanN genes encode a ligase assembling the last two amino acids or peptidoglycan
precursors, resulting in a peptidoglycan precursor with less affinity for
glycopeptides. Teicoplanin: All Vancomycin intermediate Staphylococcus aureus
(VISA) strains are cross-resistant [96]. Enterococci containing the above Van genes
render them resistant to it.
Pharmac-
okinetics
Vancomycin: Oral intake results in minimal absorption. When given IV, efficacy is
best indicated by 24 hour AUC/MIC ratio ≥ 400 associated with lower clinical
failure [97]. Adequate CSF levels are seen in infection [98]. It is renally excreted
with no tubular secretion or absorption, and creatinine clearance inversely affects its
serum level. In obese patients, the dosing should be based on actual body weight
instead of ideal weight due to increased distribution volume [99]. Therapy needs to
be monitored with trough levels (correlate with AUC/MIC ratio) to prevent toxicity.
Dose adjustment is needed with renal failure.
Teicoplanin: Poor oral absorption, 90% bound to plasma protein, and highly bound
in tissues. It reaches adequate concentrations in all tissues except for vitreous and
CSF, even with infection. It undergoes renal clearance, and dosing adjustments are
needed in renal failure. Trough levels ≥28 μg/mL are associated with hepatotoxicity.




Frequently seen when the trough levels are ≥15 μg/mL with a treatment duration of
>7 days [101].
Infusion-related reactions: red man syndrome, hypotension, and cardiac arrest.
Others: Nephrotoxicity, Ototoxicity, Neutropenia, Thrombocytopenia, and DRESS
[102–104].
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Origin Telavancin is a vancomycin derivative post alkylation [105]. Dalbavancin is a
semisynthetic derivation from teicoplanin like glycopeptide, a fermentation product




Telavancin: binds to peptidoglycan precursors, inhibits transglycosylation, and
inhibits cell wall synthesis. It also disrupts cell wall homeostasis [106]. Dalbavancin:
binds to peptidoglycan precursors with higher affinity and inhibits cell wall
synthesis. Oritavancin: Binds to peptidoglycan precursors, stops transglycosylation,
transpeptidation and inhibits cell wall synthesis. It disrupts the cell wall membrane
[107].
Routes Telavancin: available in IV formulations Dalbavancin: available in IV formulations
Oritavancin: available in IV formulations
Indication Telavancin: Acute gram-positive bacterial SSTI Dalbavancin: Acute gram-positive
bacterial SSTI Oritavancin: Acute gram-positive bacterial SSTI in adults only
Resistance Telavancin: VRE containing VanA gene are resistant to it [108]. Dalbavancin: is
bacteriostatic against VISA strains, no activity against VanA but is active against
VanB and VanC possessing bacterial strains. Oritavancin: VanZ gene and mutations




Telavancin: Tissue distribution is similar to vancomycin, 90% plasma protein
bound, undergoes renal clearance and dose adjustment needed in renal failure [105].
It is recommended to avoid use in severe acute renal failure. Dalbavancin: High
volume tissue distribution, plasma protein binding of 93%, and a half-life of 8 to
9 days. It undergoes primarily renal clearance with the remaining via feces. It
requires dose modification in renal failure [110]. The best predictor of its activity is
the 24-hour AUC/MIC. Oritavancin: High volume tissue distribution, plasma
protein binding of 85–90%, and a half-life of 10 days. It gets intracellularly retained
in the liver, kidneys, lungs, and lymphoid tissue, from where it is released slowly.
No dosage adjustment is done for mild to moderate liver or renal impairment.
Toxicity/Adverse
effects
Telavancin: prolongs the QTc interval, nephrotoxicity, nausea, vomiting, chills, and
creatinine rise. It is teratogenic. Dalbavancin: pruritis, vomiting, nausea, infusion
reactions, skin, and hypersensitive reactions. Oritavancin: nausea, headache,
vomiting, diarrhea, mild transaminitis, hypersensitive reactions. Drug interactions
can be seen as it inhibits cytochrome P450 enzymes.
Table 9.
3A II lipoglycopeptides.
Origin Daptomycin is a lipopeptide antibiotic isolated from Streptomyces roseosporus.
Mechanism of
action
It is an antimicrobial peptide of cation origin attaching to the cell wall in the
presence of calcium, disrupting the cell wall structure by displacing the cell wall
proteins and formation of an oligomer in the cell wall. This action is unalterable,
causing impaired cell wall function and leakage of ions leading to cell death
[111–113].
Routes Available in only IV formulations
Indication Acute SSTI by MSSA, MRSA, Enterococcus faecalis, streptococcal species (as an
alternative in glycopeptide therapy failure or intolerance or higher MRSA
vancomycin MIC. Acute MSSA, MRSA bacteremia, and right-sided endocarditis
[114].
Resistance Cell wall changes with increased fluidity, net positive charge, and lack of
depolarization or permeability decreased phosphatidylglycerol, leading to
daptomycin resistance. Multiple genes are involved in this, including mprF, yycFG,
vraSR, dlt, rpoB, rpoC, pgsA, and cls [115–118].
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Due to the lack of active intrinsic electron transport chain and cell membrane
potential difference, the anaerobic bacteria are resistant to aminoglycosides.
Enterococci are intrinsically resistant to aminoglycosides [228]. Once-daily dosing is
effective as traditional multiple doses, decreases the risk of ototoxicity and nephro-
toxicity, is straightforward, and is economical towards resources and time [229].
This dosing pattern does not decline neuromuscular function in sick intubated
patients but needs evaluation in cystic fibrosis, meningitis, and osteomyelitis caused
by aerobic gram-negative bacilli [230–232]. The once-daily dose should be used
Pharmac-
okinetics
It has a long half of 7.3 to 9.6 hrs with a small distribution volume and is highly
bound to plasma proteins (90% - 93%) [119, 120]. It gets excreted via the renal
system unchanged. Dose adjustment is needed in acute renal failure and dialysis
patients. It has poor penetration into CSF [121]. It is inactivated by the pulmonary
surfactant leading to ineffectiveness against bronchioalveolar pneumonia. It exerts a
dose-dependent postantibiotic effect longer than vancomycin [122].
Toxicity/Adverse
effects
Higher doses (>8 mg/kg/day) results in elevation of serum creatinine
phosphokinase (CPK) levels with no muscle cell lysis or fibrosis [123]. CPK level
monitoring during therapy is a must. Peripheral neuropathy with paraesthesia and
dysesthesia. Acute eosinophilic pneumonia (after ten days of therapy)
Table 10.
3A III lipopeptides.
Origin Aminoglycoside with the name ending in mycin is derived from Streptomyces [124].
Aminoglycoside with the name ending in micin is derived fromMicromonospora spp.




Cationic aminoglycosides bind to the anionic lipopolysaccharides and disrupt their
structure resulting in cell wall leaks and altered permeability. Once in the cytosol, it
binds reversibly to ribosomal decoder acceptance site on 16S reverse transfer RNA
portion of messenger RNA (mRNA), a 30S subunit of prokaryotic ribosomes. This
decreases the mRNA translocation and translation stopping protein synthesis [125–
128]. They demonstrate the postantibiotic effect, synergistic behavior with other
antibiotics, and concentration-dependent effect.
Routes Available in IV and oral formulations.
Indication Empirical therapy of aerobic gram-negative bacilli (GNB) including Pseudomonas
spp. As a part of a combination therapy for HAP, Enterococcal bacteremia, and IE due
to enterococcus and streptococcus spp. Acute urinary tract infection and cystic fibrosis
exacerbations. Preoperative prophylaxis in gastrointestinal and genitourinary
procedures.
Resistance Altered cell wall membrane with diminished interaction, active efflux pumps
resulting in lesser concentration in the cytosol [129, 130]. Decreased ribosomal
binding due to mutation or methylation of the binding site [131]. Inactivation of the




Plasma protein binding is low, highly soluble in water, with distribution resembling
extracellular fluid compartments [134, 135]. Appropriate concentrations are
attained in all body fluids except for CSF and vitreous humor [136–138]. They
undergo renal clearance unchanged with minimal excretion via feces [139]. Dose
adjustment is needed in renal failure.
Toxicity/Adverse
effects
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Origin Initially derived as a byproduct of chloroquine synthesis, the newer quinolones are
semisynthetic with chemical modifications to increase their efficacy and absorption.
Mechanism of
action
Inhibit deoxyribonucleic acid (DNA) synthesis by inhibiting DNA gyrase and
topoisomerase IV. It also leads to hydroxy radicals, damaging the bacterial cellular
molecules causing bacterial cell death [140, 141].
Routes Available as oral, IV, and eye drop formulations
Indication Acute cystitis, Acute uncomplicated, and cUTI. Acute Bacterial prostatitis, Sexually
transmitted disease, PID, Chlamydiae trachomatis, Hemophilus ducreyi. Acute
bacterial gastroenteritis due to Shigella spp, Campylobacter jejuni, Cholera, Typhoid,
Nontyphoidal Salmonellae gastroenteritis in specific patients.
Acute intraabdominal infections, Spontaneous bacterial peritonitis (SBP). Acute
CABP, Acute bronchitis, Aspiration pneumonia, Lung abscess, HAP,
stenotrophomonas infections. Acute osteomyelitis, Acute native and prosthetic joint
infections, SSTI. MDR pulmonary tuberculosis, Nontuberculous mycobacterial
infections, GNB susceptible organisms causing meningitis, Prophylaxis in
neutropenic patients.
Resistance Chromosomal gene mutations alter DNA gyrase, and topoisomerase IV decreases
cell membrane permeability. Plasmid-mediated genes enabling acetylation and
efflux pumps decreasing efficacy.
Pharmac-
okinetics
Excellent oral bioavailability and food can alter absorption [142]. Plasma protein
binding is low except for delafloxacin and gemifloxacin. Tissue distribution is
excellent, with above serum levels seen in bile, prostate, kidney, lung, and stool
[143]. Levofloxacin and moxifloxacin attain adequate CSF penetration [144].
Levofloxacin, ofloxacin, ciprofloxacin undergo renal clearance, whereas




GI: vomiting, nausea, abdominal discomfort, diarrhea, Clostridioides difficile
associated diarrhea [146]. CNS: headache, dizziness, mood changes, peripheral
neuropathy [147, 148]. Skin: allergy and skin reactions such as maculopapular rash,
phototoxicity [149, 150]. Others: hypoglycemia, prolongs QT interval, increased risk




Origin PCN was isolated from Penicillium chrysogenum in 1928 by Alexander Fleming [156].
Chemical modifications created numerous semisynthetic PCNs. Natural PCNs: PCN
V, PCN G. Penicillinase resistant PCN: Methicillin. Nafcillin, Oxacillin.
Aminopenicillins: Amoxicillin, Ampicillin. Carboxypenicillins: Ticarcillin and
Carbenicillin. Ureidopenicillins: Piperacillin, Azlocillin and Mezlocillin.
Mechanism of
action
PCNs bind to multiple PBP simultaneously, stopping the cell wall synthesis and
creating hydroxy radicals that permanently damage the cell. PCNs do not affect
dormant bacteria [141, 157].
Routes Oral, IV, and intramuscular (IM) formulations are available.
Indication IV PCN G is the antibiotic of choice for PCN susceptible strains causing
pneumococcal and meningococcal meningitis, streptococcal IE, and neurosyphilis.
Benzathine PCN is used in syphilis treatment and for rheumatic fever prophylaxis.
Oral PCN V or G or Benzathine PCN are used to stop outbreaks of streptococcal
infection. Intrapartum prophylaxis with PCN is used at membrane rupture or at
labor to prevent Streptococcal agalactiae infections in colonized patients. PCNase
resistant PCNs are the agent of choice for MSSA infections and an alternative to
treat streptococcal infections. AminoPCNs treat UTI, Upper and lower airway
infections, Gastroenteritis, IE, Meningitis by susceptible non-beta- lactamase
organisms. IV ampicillin is the treatment of choice for Enterococcus faecalis IE and
other infections. Amoxicillin is a part of the combination regimen against
Helicobacter pylori. Oral amoxicillin or ampicillin are used as prophylaxis in asplenic
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or agammaglobulinemia patients to prevent infections by capsulated organisms.
Ampicillin-sulbactam is the drug of choice for aspiration pneumonia. Piperacillin-
tazobactam is an antipseudomonal and is also used for necrotizing fasciitis,
susceptible GNB infections.
Resistance Presence of beta-lactamase [158]. Alteration of cell membrane permeability with a
decreased intracellular entry (absence of porin) [159]. Presence of efflux pumps
[159]. Synthesis of PBP with decreased affinity for the beta-lactam [160].
Pharmac-
okinetics
PCNs vary in their oral absorption and plasma protein binding. The tissue
distribution is more than adequate in most tissues. The primary route of excretion is
via the renal system, whereas some undergo biliary excretion too.
Toxicity/Adverse
effects
Hypersensitivity reactions: rash, anaphylaxis, exfoliative dermatitis, allergic
vasculitis, SJS, and TEN [161]. GI: nausea, vomiting, diarrhea, Clostridioides
difficile associated diarrhea, liver function test abnormality with oxacillin in patients
with HLA-B 5701 [162, 163]. Hematological: neutropenia [164]. Renal:
Nephrotoxicity, allergic interstitial nephritis [165]. CNS: Myoclonic seizures.
Table 13.
3A VI penicillin (beta-lactams).
Origin Semisynthetic derivatives of Cephalosporin C isolated from Acremonium
chrysogenum [166]. First-generation: cefazolin, cephalexin, and cefadroxil. Second
generation: cefprozil and cefuroxime, cephamycin: cefoxitin Third generation:
cefdinir, cefditoren, cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftibuten,
ceftriaxone. Fourth generation: Cefepime, Cefpirome. Fifth-generation: Ceftaroline,
ceftobiprole. Siderophore cephalosporins: Cefiderocol.
Mechanism of
action
They bind to PBPs and stop transpeptidation and block the cell wall synthesis
resulting in a bactericidal effect with a postantibiotic effect [167]. MRSA active
cephalosporins bind to PBP2A, whereas the other cephalosporins bind to PBP1A&B
in gram negatives [168]. Cephalosporins active against gram-positive organisms
bind to PBP 2&3 (186). Cefiderocol binds to iron and enters the bacteria via
siderophores into the periplasmic space and binds to PBP in addition to being a poor
substrate for efflux pumps [169].
Routes First, second and third generations are available in oral and parenteral (IV/IM)
formulations. The fourth and fifth-generation are available in IV formulations.
Fifth-generation are available in IV formulations. Siderophore cephalosporins:
available in IV formulations.
Indication First-generation: oral therapy for MSSA and Streptococcal SSTI outpatient,
susceptible Streptococcal SSTI, MSSA IE, the prophylactic antibiotic of choice for
prosthesis implantation and surgical procedures with a high risk of infection except
for intraabdominal procedures. Second generation: as a part of a combination
regimen for PID (cefoxitin), nontuberculous mycobacterial infection (cefoxitin),
cefuroxime for acute otitis media, pharyngitis, maxillary sinusitis, and an alternative
for Lyme disease [170, 171]. Third generation: treatment of susceptible GNB bacilli
induced SSTI, Prosthetic joint infection (PJI), CABP, cUTI, and peritonitis [172].
Empirical therapy for CABP, acute bronchitis, and meningitis. IM single dose for
Neisseria gonorrhea and chancroid [173]. Lyme disease and an alternative for PCN
allergic patients with syphilis, typhoid fever, and shigellosis [174, 175].
Monotherapy for Streptococcal IE [176]. Ceftazidime is the drug of choice for
susceptible Pseudomonas spp infections, including CNS [177]. Fourth generation:
antibiotic of choice for infections caused by AmpC (Class C beta-lactamases)
inducible resistant organisms [178]. Febrile neutropenia monotherapy or a part of a
combination regimen [179]. Empirical therapy in severe CABP, HAP by
Pseudomonas spp or resistant Enterobacteriaceae [180]. It is an alternative for
susceptible GNB meningitis, bacteremia, SSTI, PJI and cUTI. Fifth-generation:
Ceftaroline used for MRSA pneumonia, CABP, SSTI, HAP, and in combination with
daptomycin for daptomycin resistant MRSA infections [181–183]. Ceftobiprole also
is an alternative for Pseduomonal spp infections. Siderophore cephalosporins:
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approved for use in cUTI by Enterobacterales & P. aeruginosa, HAP, and VAP by the
Enterobacterales, P. aeruginosa, and Acinetobacter baumannii complex [169].
Resistance Beta-lactamase hydrolyzes the antibiotic. Cell wall membrane changes alter the
entry of antibiotics through the lipopolysaccharide layer. Efflux pumps removing
the antibiotic from the periplasmic space. PBP changes to alter antibiotic binding.
Pharmac-
okinetics
The first three generations are water-soluble and come in oral and parenteral
formulations, whereas the fourth and fifth-generation are parenteral only.
Distribution is dependent on their lipid solubility and plasma protein binding. They
reveal higher serum concentrations and lower tissue levels. The third and fourth
generations attain adequate CNS concentrations. Most of them undergo renal
clearance except for ceftriaxone and cefoperazone, which undergo biliary excretion.
Probenecid inhibits tubular secretion of cephalosporins and increases their half-life.
Renal failure will need a dose adjustment. Ceftriaxone dose is adjusted with
simultaneous renal and hepatic impairment [184]. Cefiderocol is excreted renally
and needs renal dose adjustment [185].
Toxicity/Adverse
effects
Hypersensitivity reactions: immunoglobulin E (IgE)-mediated reactions occur in
<1 in 100,000 patients; fever, rash, eosinophilia, serum sickness, and anaphylaxis
are seen. Cross-reaction frequency is ≤1%. Hematology: eosinophilia, neutropenia
(prolonged use), anemia, thrombocytopenia, hypoprothrombinemia, impaired
platelet aggregation, hemolytic anemia (ceftriaxone). Nephrology: allergic
interstitial nephritis GI: nausea, vomiting, diarrhea, Clostridioides difficile infection,
biliary pseudolithiasis (ceftriaxone), transaminitis. CNS: seizures, encephalopathy
Others: fever, disulfiram-like reaction, phlebitis.
Table 14.
3A VII cephalosporins.
Combinations Augmentin = Amoxicillin + Clauvulinic acid in an 2:1, 4:1,7:1 ratio (isolated from
Streptomyces clavuligerus [186]. Unasyn = Ampicillin + Sulbactam in an 2:1 ratio
Sulperazone = Cefoperazone + Sulbactam in an 1:1 ratio Zosyn = Piperacillin +
Tazobactam in an 8:1 ratio Zerbaxa = Ceftolazone + Tazobactam in a 2:1 ratio
Avycaz, Zavicefta = Ceftazidime + Avibactam in a 4:1 ratio Vabomere = Meropenem
+ Vaborbactam in a 1:1 ratio
Mechanism of
action
Clavulanic acid: is potent and inhibits class A beta-lactamase and some extended-
spectrum beta-lactamases (ESBL). Sulbactam: is a broad-spectrum inhibitor than
clavulanic acid but less potent (inhibits class A beta-lactamases). Tazobactam:
spectrum is similar to sulbactam but is more potent. Avibactam: inhibits class A
beta-lactamases, including ESBL, Klebsiella pneumoniae carbapenemase (KPC), class
C, and some class D beta-lactamases. It does not stop Metall0beta-lactamases
(MBL). Vaborbactam: inhibits class A beta-lactamases including ESBL, KPC, class C
beta-lactamases with no effect on MBL and class D beta-lactamases.
Routes Augmentin: available orally and IV formulations. Unasyn: available in IV
formulations Sulperazone: available in IV formulations Zosyn: available in IV
formulations Zerbaxa: available in IV formulations Avycaz, Zavicefta: available in
IV formulations Vabomere: available in IV formulations
Indication Augmentin: acute otitis media, acute sinusitis, outpatient CABP by susceptible
organisms with a higher dose, diabetic foot infection, SSTI, human or animal bites.
Unasyn: as a part of a combination regimen against MDR Acinetobacter baumannii
infection, SSTI, cIAIs, and obstetric and gynecological infections. Sulperazone:
treatment of A. baumannii infection Zosyn: treatment of pneumonia, SSTI, cIAIs,
febrile neutropenia, and polymicrobial infections [187]. Zerbaxa: indicated in cUTI,
cIAIs, and Carbapenemase resistant Pseudomonas aeruginosa infections. Avycaz,
Zavicefta: indicated in cUTI, cIAIs, HAP, and KPC Enterobacteriaceae infections.
Vabomere: indicated in KPC Enterobacteriaceae infections and cUTI.
Resistance Augmentin: plasmid-mediated beta-lactamase TEM-1 and OXA-1 (Oxacillin beta-
lactamases) [188]. Unasyn: cephalosporinase, ESBL, and carbapenemase production
by resistant strains. Sulperazone: cephalosporinase, ESBL, and carbapenemase
13
Bactericidal and Bacteriostatic Antibiotics
DOI: http://dx.doi.org/10.5772/intechopen.99546
Please use Adobe A robat Reader to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter t the Web Viewer here.
Securing Connection...Acrobat is l cking documen loading.com
r
File cannot be found.
cautiously in IE patients [176]. Inhaled aminoglycosides used in conjunction with a
beta-lactam reveal better clinical outcomes [233]. For endophthalmitis and intra-
cranial infections, they need to be administered locally (direct intravitreal injection,
intraventricular administration). Aminoglycoside combination regimens diminish
the emergence of resistant strains to the companion antibiotic and aminoglycoside.
The synergistic antibiotic effect is observed when aminoglycoside is combined with
an anti-cell wall antibiotic (beta-lactam). This combination is effective in the ther-
apy of MSSA, enterococci, pseudomonas spp, and Streptococcal viridans infections but
not in MRSA infections.
production by resistant strains. Zosyn: ESBL and carbapenemase production by
resistant strains. Zerbaxa: carbapenemase production KPC, OXA, ESBL, and MBL
by resistant strains. Avycaz, Zavicefta: porin mutations, efflux pumps, and MBL.
Vabomere: coproduction of KPC and class B or D beta-lactamases, porin mutations,
and efflux pumps [189].
Pharmac-
okinetics
Augmentin: well absorbed orally and undergoes renal clearance with dosing
adjustment needed in renal impairment. It does not penetrate CSF but reaches
therapeutic levels in the peritoneum, bile, tonsils, and middle ear. Unasyn: renally
cleared and dose adjustment needed in renal insufficiency. Levels in peritoneal and
intestinal fluids are the same as in serum with minimal CSF penetration.
Sulperazone: available in IV formulations Zosyn: renally cleared and will need a dose
adjustment and minimal CSF penetration. Zerbaxa: renally cleared and will need a
dose adjustment. Avycaz, Zavicefta: gets excreted renally unchanged, and dosage
adjustment is a must when creat clearance is <50 mL/min. Vabomere: the majority




Augmentin: skin reactions, delayed hypersensitivity, diarrhea, and nausea. Unasyn:
occasional transaminitis and similar reactions as seen with ampicillin Sulperazone:
occasional transaminitis and similar reactions as seen with ampicillin. Zosyn: platelet
dysfunction, immune thrombocytopenia, allergic reactions, renal failure,
Clostridioides difficile infection [190, 191]. Zerbaxa: headache, nausea, diarrhea,
Clostridioides difficile infection Avycaz, Zavicefta: anxiety, nausea, vomiting, and
constipation. Vabomere: phlebitis, headache, diarrhea, and infusion site reactions.
Table 15.
3A VIII beta-lactamase inhibitors and beta-lactam combinations.




It avidly binds to PBP3 of aerobic GNB, inhibiting cell wall synthesis resulting in
death [192]. It remains active against all class B beta-lactamases and the majority of
class A and D beta-lactamases. It is destroyed by KPC, ESBLs, and AmpC beta-
lactamases if present in a larger quantity.
Routes Available in IV formulations.
Indication As an alternative in susceptible aerobic GNB infections in patients with beta-lactam
allergy. As a part of a combination regimen against MBL producing GNB infections.
Resistance It is via efflux pumps and alterations to the PBP3 binding site [193].
Pharmac-
okinetics
Orally it is absorbed poorly with 56% plasma protein binding after IV
administration. Excellent tissue distribution with CSF penetration. Excretion is




Nausea, vomiting, diarrhea, rash, phlebitis [194]. Crossreaction with other beta-
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Origin They are semisynthetic derivatives from thienamycin, an antibiotic isolated from
Streptomyces cattleya. The human renal enzyme dehydropeptidase breaks down
imipenem and is combined with cilastatin which inhibits this enzyme.
Mechanism of
action
They gain entry into the periplasmic space via porins located on the cell wall and
avidly bind to the PBPs 1a, 1b, 2, 4, and also to PBP3 minimally. This stops the cell
wall synthesis and leads to the death of the bacteria. They are inactive against
organisms producing MBL or class B beta-lactamases such as Stenotrophomonas
maltophilia and Elizabethkingia meningoseptica. Ertapenem has minimal activity
against Pseudomonas and Acinetobacter spp. Imipenem is partially active against
Enerococcus faecalis [195].
Routes IV formulations: Imipenem. Meropenem, Ertapenem, Doripenem. Oral
formulations: Tebipenem in Japan.
Indication Treatment of bacterial meningitis, Pseudomonas spp, and ESBL bacterial infections.
An alternative choice for infections caused by AmpC organisms. Treatment of
infections such as bacteremia, cUTI, cIAI, HAP, SSTI, nocardiosis, and
actinomycosis.
Resistance Beta-lactamase synthesis breaks down carbapenem such as KPC, OXA, and MBL.
Decreased cell wall entry due to porin mutations or lack of porins. Efflux pumps.
Alterations in PBPs site resulting in less avid binding of the carbapenem.
Pharmac-
okinetics
Poor oral absorption except for Tebipenem. Plasma protein binding, if higher, leads
to a longer half-life (Ertapenem) and once-daily dosing. Tissue distribution and
penetration are excellent, including CSF [195]. Excretion is via the renal route, and




Phlebitis, nausea, vomiting, headache, diarrhea, rash, and Clostridioides difficile
infection. Seizures, especially with imipenem. Interact with valproic acid and lead to
subtherapeutic valproate levels [196]. Potential crossreactivity exists between PCN




Origin Polymixin B is semisynthetically derived from a biochemical product from Bacillus
polymyxa. Polymixin E (Colistin) is semisynthetically derived from a biochemical
product from Bacillus colistinus. It is commercially available in an inactive prodrug
methanesulfonate (CMS) which is converted to colistin invivo.
Mechanism of
action
It is a surface-active agent with both lipophilic and lipophobic subunits which
infiltrate the outer cell membrane of GNB. Then they interact with the
phospholipids electrostatically, resulting in cell membrane destruction. They bind
avidly to lipid A portion of lipopolysaccharide and stop its endotoxin effect [198].
Routes Polymixin B: available in oral, IV/IM, and topical formulations. Polymixin E:
available in oral, IV/IM, inhalation, and topical formulations.
Indication Polymixin B favored over CMS in all infections except in UTI. Oral preparations are
used for intestinal decontamination. Administered intraventricularly for GNB
meningitis. Inhaled CMS for infections in Cystic fibrosis. Parenteral administration
for severe systemic infections caused by MDR GNB, including VAP.
Resistance Resistance is mediated via the plasmid-mediated MCR-1, MCR-2, and MCR-3,
which alter the lipopolysaccharide structure and prevent polymixin binding [199].
Cross-resistance between the polymyxins is complete [200].
Pharmac-
okinetics
They are poorly absorbed, and post IV administration, the distribution to the biliary
tract, CSF, joint and pleural fluid is low. CMS undergoes renal clearance, so the dose
needs to be adjusted in renal impairment. Both colistin and polymyxin undergo
nonrenal clearance (Unknown exact mechanism) after extensive tubular
reabsorption with no need for renal dose adjustment [201].
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Plazomicin is a semisynthetic aminoglycoside derived from sisomicin. It is
potent against MDR GNB, especially the ones with carbapenemase. It has been
approved currently for the treatment of complicated UTI (cUTI) by aerobic
Origin It was isolated from the soil bacteria Streptomyces fradiae.
Mechanism of
action
It inhibits phosphoenolpyruvate synthetase, an enzyme needed to synthesize N-
acetylmuramic acid, an essential component of cell wall formation, thus inhibiting
cell wall formation. Its bactericidal effect is broad, covering resistant gram-negative
and gram-positive microorganisms [203, 204].
Routes Available in IV and oral formulations. Only oral formulation is currently approved.
Indication The oral form has been approved for uncomplicated UTI due to susceptible strains
of Escherichia coli and Enterococcus faecalis. IV formulation has been used in a
combination regimen against deep-seated infections due to MDR organisms.
Resistance Modification of phosphoenolpyruvate synthetase enzyme, porin mutations, and




It undergoes renal clearance with dose adjustment needed in renal impairment.
Higher doses are associated with bradycardia [205].
Toxicity/Adverse
effects
Hypernatremia, hypokalemia, hypocalcemia, and phlebitis.
Table 19.
3A XII epoxide (fosfomycin).
Toxicity/Adverse
effects
Dose-related nephrotoxicity is frequent with colistin than polymyxin B seen as renal
impairment often reversible on stopping the medication. Dose-related neurotoxicity
manifesting as neuromuscular blockade resulting in muscular weakness, apnea, and
respiratory failure. This effect can be augmented on concurrent administration with




Origin It is isolated from the fungus Pleurotus mutilus.
Mechanism of
action
It inhibits protein synthesis by binding to 23SrRNA part of the 50S ribosome
subunit. Its activity against gram-positive organisms is potent invitro (MSSA/
MRSA/Streptococcal spp). Its spectrum of bactericidal effects is broad, covering both
gram-positive and negative respiratory pathogens.
Routes Available in both oral and IV formulations.
Indication It is approved for CABP therapy in patients >18 years old by both IV and oral
formulations.
Resistance Mutations in the 23S rRNA and methylation of the target site preventing Lefamulin
from 23S rRNA binding [206].
Pharmac-
okinetics
It undergoes hepatic clearance by cytochrome CYP3A and can lead to interactions.
Dose adjustment is needed in hepatic impairment and none in renal failure.
Toxicity/Adverse
effects
Infusion site reactions, phlebitis, headache, nausea, diarrhea, and QT prolongation
[207].
Table 20.
3A XIII pleuromutilin (lefamulin).
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gram-negative bacilli. It is synergistic with other beta-lactams, especially zosyn
cefepime and doripenem [234]. The main side effects are tinnitus, headache, dizzi-
ness, and mild to moderate drowsiness.
Delafloxacin, a newer quinolone, has MRSA activity and can be used in native
and prosthetic joint infections as an oral pill.
Origin Rifampin was semisynthetically obtained from rifamycin SV isolated from




Rifamycins bind avidly to DNA-dependent RNA polymerase and block RNA
synthesis.
Routes Rifampin: available in oral and IV formulations. Rifabutin, Rifapentine, Rifaximin:
available in oral formulations.
Indication Rifampin: Antitubercular therapy for active tuberculosis. Treatment of
Nontubercular mycobacterial infections due to Mycobacterium leprae (M. leprae),
Mycobacterium avium-intracellulare (MAC), Mycobacterium kansasii.
Combination therapy for synergistic antistaphylococcal effect and antibiofilm effect
in PJI, chronic osteomyelitis, and SSTI. Therapy for resistant Streptococcus
pneumoniae strains causing CNS infections and Enterococcal hip and knee PJI.
Therapy for severe legionella infection along with a macrolide. As a part of
combination therapy of Rhodococcus equi infections in immunosuppressed patients.
As a part of combination therapy of MDR GNB infections. Brucellosis and
complicated Bartonella infection antimicrobial therapy. Chemoprophylaxis in
Meningococcal meningitis and ActiveHemophilus influenzae infection close contacts.
Rifabutin: As an alternative to rifampin in the treatment of tuberculosis and MAC
infection.
Rifapentine: As a part of the short regimen for latent tuberculosis therapy,
Rifaximin: Hepatic encephalopathy treatment, Alternative for travelers diarrhea and
recurrent Clostridioides difficile infection. It is an alternative for GI invasive
pathogens Salmonella, Shigella, Campylobacter, and Escherichia coli.
Resistance rpoB gene mutations result in decreased binding of rifamycins to RNA polymerase
[208]. Decreased cellular uptake of rifampin. Mutations in the arr gene lead to
ribosylation of rifamycins and decreased binding [209].
Pharmac-
okinetics
Rifampin: excellent oral bioavailability with broad tissue and fluid distribution,
including brain [210]. It undergoes hepatic clearance, enterohepatic circulation with
biliary excretion, and minimal renal excretion. Dosage adjustment is needed in
hepatic impairment. It induces hepatic enzyme CYP3A resulting in drug
interactions, especially with protease inhibitors. Rifabutin: is more lipid-soluble with
a long half-life and extensive tissue distribution, including CSF. Its metabolites post
hepatic metabolism undergo renal clearance, so dose adjustment is needed with
hepatic and renal impairment. Hepatic enzyme induction is minimum. Protease
inhibitors increase their levels. Rifapentine: Food increases its bioavailability, and it
is more potent with a longer half-life. Intracellular concentrations are higher than
rifampin with minimal CSF penetration. It undergoes hepatic clearance with
induction of hepatic enzymes CYP3A4 and protease inhibitors decrease its
absorption [211]. Rifaximin: Oral absorption is minimal, and 97% of the drug gets
excreted in stools. It can induce cytochrome P450 3A4, but it is not seen as the
systemic levels are minimal [212]. No dosage adjustment is required.
Toxicity/Adverse
effects
Rifampin: type 1 hypersensitivity reactions, flu-like syndrome, hemolysis,
thrombocytopenia, acute interstitial nephritis with tubular necrosis, mild
transaminitis with increased risk of hepatotoxicity with isoniazid [213], and red-
orange discoloration of body fluids. Rifabutin: polyarthralgia, leukopenia, and
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PCN skin tests are inaccurate in predicting skin reactions. In PCN or cephalo-
sporin allergy patients, the clinical decision to use a different cephalosporin is
decided by the severity of the reaction and the cephalosporin to be used. In patients
with no severe reactions, a cephalosporin with a different side chain can be used. It
is recommended not to use a cephalosporin in case of a severe reaction [235].
Cephalosporins are not active against atypical organisms responsible for CABP. An
initial study disclosed increased mortality with cefepime than other cephalosporins
compared to a beta-lactam plus beta-lactamase inhibitor (BLI), which was not
observed in a more extensive meta-analysis [236, 237]. Cefepime is not
recommended to be used in ESBL infections [238]. Siderophore cephalosporins
Cefiderocol are active against all beta-lactamases and carbapenemase enzymes
[239]. It is also active against the GNB lactose-non fermenters by its affinity for the
PBP3.
Zosyn should not be used to treat ESBL infections with bacteremia due to higher
mortality observed in trials compared to meropenem [240, 241].
Most Burkholderia cepacia, Stenotrophomas maltophilia, Acinetobacter baumannii
strains are resistant to aztreonam.
Lactose-non fermenters such as Stenotrophomonas maltophilia, B. cepacia, and
Elizabethkingia meningoseptica are intrinsically resistant to all carbapenems due to
intrinsic MBL synthesis. Similarly, Enterobacteriaceae containing KPC (Klebsiella
pneumoniae), OXA (A. baumannii), or acquired MBL are resistant to carbapenems.
They are an ideal choice for polymicrobial infections as they also cover MSSA.
Pseudomonas aeruginosa resistance to carbapenems is primarily due to porin
Origin It is a semisynthetic derivative of azomycin isolated from a streptomyces bacterium.
Tinidazole, Secnidazole and Ornidazole are the other semisynthetic derivatives.
Mechanism of
action
It enters the cell passively and then gets an electron transferred to its nitro group,
creating a free radical which is cytotoxic and interacts with DNA (prodrug to an
active drug). This change enhances the drug gradient in the cell by increased uptake.
The active drug oxidizes DNA damaging it and block DNA synthesis [215].
Routes Available in oral capsules, tablets, topical gels, creams, lotion, vaginal gel,
suspension, and IV formulations.
Indication Treatment of parasitic infections such as trichomoniasis, symptomatic GI
Dientamoeba fragilis infection, Giardiasis, mild to moderate Clostridioides difficile
infection, anaerobic infections of CNS, lung, abdomen, Skin, gynecologic, oral,
dental, bone, and joint. As a part of a combination regimen against Helicobacter
pylori. As an alternative agent recommended for surgical prophylaxis in
intraabdominal, head, and neck cancer, urology surgery for patients intolerant or
allergic to beta-lactams [216]. Prophylaxis perioperatively in obstetric and
gynecologic procedures [217].
Resistance Decreased uptake of the antibiotic. Active drug efflux pumps. Reduced activation of
the prodrug (↓nitroreductase enzymes). Inactivation of the antibiotic (nim-
encoded nitroimidazole reductase). Altered DNA repair [215].
Pharmac-
okinetics
Oral bioavailability is close to 100%, with a more considerable volume of
distribution attaining excellent concentrations in tissue, body fluids, abscess, and
CSF [10]. It undergoes hepatic clearance and enterohepatic circulation with some




Common ones include nausea, metallic taste, dry mouth, diarrhea, vaginal candida
infection, CNS side effects on prolonged therapy (aseptic meningitis,
encephalopathy, ataxia, seizure). Rare serious events include ototoxicity, Stevens-
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mutations and efflux pumps than the carbapenemase. Porin mutations affect the
imipenem, whereas the efflux pumps affect the meropenem and doripenem
[242, 243]. The duration of therapy for lactose-non fermenters causing VAP is
controversial, as a shorter duration of seven days is associated with an increased
recurrence rate [244].
Compared to other antimicrobial classes, polymixins have been associated with
poorer outcomes, but this appears to be a poor application of prior suboptimal dose
adjustments based on the newer pharmacokinetics and pharmacodynamics data
[245, 246]. Polymixin combination regimens should be used as a last resort in the
absence of any alternative antimicrobial regimen.
Extreme consideration should be given to the possible drug interactions when
rifamycins are used clinically due to their ability to induce the hepatic cytochrome
system.
4. Antibiotics in ICU
Antimicrobial prescription in the intensive care unit has three essential ideals to
be followed: the correct time when to initiate the antimicrobial, what dose to be
used, and how long the antimicrobial should be used. Initiate empirical regimen as
early as possible once the infection is suspected to prevent poor clinical outcomes
[247]. Trials reveal a positive association between earlier antimicrobial use and
mortality in sepsis and septic shock [248]. 2016 surviving sepsis guidelines recom-
mend administering appropriate antimicrobial therapy within one hour of sepsis
and septic shock recognition based on the moderate quality of evidence [249]. The
empirical regimen should be based on the clinical presentation and associated risk
factors. The dose used should be based on the antimicrobial pharmacokinetics, and
antibiotics are labeled as either time-dependent (beta-lactams), concentration-
dependent (aminoglycosides and daptomycin), and concentration-dependent with
time dependence (fluoroquinolones, linezolid) [250].
For time-dependent antimicrobials, the best way to achieve efficacy is a contin-
uous infusion to keep the drug levels above the MIC for a longer time [251]. For
concentration-dependent antimicrobials, once-daily higher doses are adequate as
they demonstrate postantibiotic effect with reduced adverse events [252]. It is
prudent to increase the antimicrobial dosage in patients with augmented renal
clearance (burns, trauma, febrile neutropenia) to increase the antimicrobial dosage
to achieve the target drug levels [253]. De-escalation of antibiotics is done via three
different methods. First, once empirical therapy is initiated, follow the pending
culture results, and on day three, when the antimicrobials have reached adequate
therapeutic levels, the regimen can be de-escalated to a narrower spectrum based on
the patient’s culture results and clinical diagnosis. Second, in patients with negative
culture results, which is a common finding in ICU patients, the de-escalation pro-
cess is unclear. For example, in patients treated for HAP who are clinically improv-
ing with negative sputum cultures for MRSA and P. aeruginosa, antibiotics covering
these organisms can be stopped as per guidelines [254]. The third mechanism uses
the empirical regimen for the shortest duration possible for a better clinical outcome
[255]. This recommendation is based on expert opinion than clinical data.
Recent guidelines based on multiple trials conducted on the VAP antimicrobial
therapy duration suggest using the treatment for seven days than 14 days [256].
However, they also recommend following the improvement in clinical, imaging,
and laboratory parameters to decide the duration of therapy judiciously. Seven days
of VAP therapy was associated with an increased recurrence of infections among
lactose-non fermenter GNB such as Pseudomonas and Acinetobacter spp. [244].
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Similarly, in MRSA and MSSA pneumonia, the duration is decided by the clinical
picture, and most often, it is more than seven days and closer to 14 days.
Antibiotic use in the intensive care unit (ICU) usually follows two different
thought processes. One way is to use a single or limited number of antimicrobials as
workhorse agents as empirical therapy for infections which carries an inherent risk
of resistance emergence via selective pressure (antibiotic homogeneity). This was
initiated to control resistance. Another way is to select the antibiotics based on
clinical presentation and comorbid risk factors associated with decreased resistance
(antibiotic heterogeneity). This is a newer initiation in managing resistance. It is
recommended to use antibiotic heterogeneity as much as possible to prevent anti-
microbial resistance emergence [257]. Antibiotic stewardship is a must in this mod-
ern era for better clinical outcomes, prevent antibiotic adverse events and resistance
using local data, reduce the costs by selecting the correct antibiotic dose duration
and route. An ideal stewardship team should include an infectious disease consul-
tant, clinical microbiologist, infectious disease trained clinical pharmacist. The cur-
rent guidelines recommend two strategies to attain this objective. First, reduce the
future antibiotic use by auditing institutional antimicrobial usage with feedback to
the prescribers. Second, it is ideal to restrict certain antimicrobials to prevent
inappropriate usage and decrease institutions’ economic burden. Measures taken to
enhance the ICU staff education boosts the stewardship process and increases its
acceptance among health care workers.
5. Conclusion
Antibiotic resources are finite and need to be managed judiciously with princi-
ples based on antimicrobial stewardship. Management of sick patients in ICU will
need timely appropriate antimicrobial adjustments based on new laboratory results
and clinical parameters. It seems reasonable to utilize a stewardship team to support
the intensivist in the ICU for better outcomes. It seems appropriate to extend the
stewardship program to progressive care units or step-down units where antimi-
crobial utilization is greater than the floors. Education of the ICU staff and positive
feedback to antibiotic prescribers can change prescription behavior from antibiotic
homogeneity to antibiotic heterogeneity to prevent the emergence of MDR
organisms.
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Acronyms and abbreviations
MIC Minimum inhibitory concentration
MBC Minimum bactericidal concentration
CLSI Clinical and Laboratory Standards Institute





UTI Urinary tract infection
TMP-SMX Trimethoprim and sulfamethoxazole
SSTI Skin and soft tissue infections
PCJ Pneumocystis jiroveci
foiP Dihydrofolate reductase encoding gene
SJS Steven-Johnson syndrome
TEN Toxic epidermal necrolysis
GI Gastrointestinal
MSSA Methicillin-sensitive S. aureus
MRSA Methicillin-resistant S. aureus
CABP Community-acquired bacterial pneumonia
PID Pelvic inflammatory disease
CSF Cerebrospinal fluid
CNS Central Nervous System
MICU Medical intensive care unit
cIAIs Complicated intraabdominal infections
MDR Multidrug-resistant
FDA Federal drug authority
HAP Hospital-acquired pneumonia
VAP Ventilator-associated pneumonia
rRNA ribosomal ribonucleic acid
PCN Penicillin
MAC M. avium complex
MLSB Macrolide Lincosamide and streptogramin B
Erm Erythromycin ribosome methylation
HLA Human leukocyte antigen
DRESS Drug rash with eosinophilia and systemic symptoms
AUC Area under the curve
VRE Vancomycin-resistant Enterococcus
optrA Adenylation coding gene
EF-G Elongation factor G
fusA Elongation factor G coding gene
PBP Penicillin-binding protein
mecA&C Methicillin resistance encoding gene
Van Vancomycin resistance encoding gene






SBP Spontaneous bacterial peritonitis
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IM Intramuscular




KPC K. pneumoniae carbapenemase
MBL Metallo-beta-lactamase
OXA Oxacillin beta-lactamases
AmpC Class C beta-lactamses
CMS Methanesulfonate
MCR Lipopolysaccharide encoding gene
rpo RNA polymerase rifamycin binding target encoding gene
arr Methytransferase encoding gene
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